[Regression of diffuse large B-cell lymphoma after discontinuation of salazosulfapyridine].

[Rinsho ketsueki] The Japanese journal of clinical hematology(2022)

引用 0|浏览2
暂无评分
摘要
An 81-year-old man with a 3-year history of salazosulfapyridine (SASP) therapy for rheumatoid arthritis (RA) presented with pulmonary infiltrates and underwent computed tomography-guided biopsy. The histopathological and immunohistochemical evaluation confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). He was recommended chemotherapy, which he refused. Due to the possibility of other iatrogenic immunodeficiency-associated lymphoproliferative disorders, SASP therapy was discontinued. SASP therapy withdrawal led to near-complete resolution of the lung infiltration shadows, and the serum soluble interleukin 2 receptor level returned to the normal range. This is the first report of a case of remission of DLBCL, following SASP therapy withdrawal in a patient with RA.
更多
查看译文
关键词
Diffuse large B-cell lymphoma,Other iatrogenic immunodeficiency-associated lymphoproliferative disorders,Rheumatoid arthritis,Salazosulfapyridine
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要